Table 3. Association between VEGFR polymorphisms and sunitinib outcome in mRCC.
| Gene SNPs | First author, year | Allele/Genotype | PFS HR (95% CI) | P value | OS HR (95% CI) | P value | Analysis method |
|---|---|---|---|---|---|---|---|
| VEGFR1 rs9582036 (A>C) | Dornbusch, 2016 | AA+AC vs CC | 0.550 (0.197–1.533) M 0.721 (0.362–1.434) U | 0.253 M 0.351 U | 0.294 (0.092–0.938) M 0.294 (0.128–0.676) U | 0.039 M 0.004 U | M/U |
| Beuselinck, 2016 | AA+AC vs CC | 0.404 (0.213–0.767) M 0.25 (0.10–0.63) U | 0.0056 M 0.003 U | 0.298 (0.159–0.559) M 0.18 (0.07–0.47) U | 0.0002 M 0.0004 U | M/U | |
| Beuselinck, 2014 | AA+AC vs CC | NA | NA | 0.2493 (0.07778–0.7992) M | 0.008 M | M | |
| VEGFR1 rs9554320 (C>A) | Dornbusch, 2016 | CC+AC vs AA | 1.454 (0.688–3.070) M 1.107 (0.672–1.823) U | 0.327 M 0.690 U | 1.233 (0.504–3.015) M 0.959 (0.504–1.825) U | 0.646 M 0.899 U | M/U |
| Beuselinck, 2016 | CC+AC vs AA | 0.486 (0.299–0.787) M 0.33 (0.18–0.62) U | 0.0034 M 0.0005 U | 0.488 (0.306–0.775) M 0.38 (0.21–0.67) U | 0.0024 M 0.0009 U | M/U | |
| Beuselinck, 2014 | CC+AC vs AA | NA | NA | 0.437 (0.220–0.872) M | 0.067 M 0.019 U | M | |
| VEGFR2 rs1870377 (T>A) | Liu, 2017 | AA vs TT | NA | NA | 3.526 (2.852–5.629) U | <0.001 U | U |
| Dornbusch, 2016 | AA+AT vs TT | 1.005 (0.620–1.630) M 0.929 (0.626–1.378) U | 0.984 M 0.714 U | 0.799 (0.428–1.494) M 0.807 (0.467–1.393) U | 0.482 M 0.441 U | M/U | |
| Garcia-Donas, 2011 | AA vs TT | 1.09 (0.68–1.74) M | 0.71 M | 1.74 (0.91–3.32) M | 0.092 M | M | |
| VEGFR3 rs307826 (A>G) | Dornbusch, 2016 | GG+GA vs AA | 0.460 (0.125–1.694) M 0.645 (0.382–1.088) U | 0.243 M 0.100 U | 0.907 (0.150–5.481) M 1.245 (0.640–2.419) U | 0.915 M 0.519 U | M/U |
| Motzer, 2014 | GG vs AA | 0.94 (0.23–3.81) U | 0.929 U | NA | NA | U/NA | |
| Beuselinck,2013 | GG+GA vs AA | 1.800 (0.996–3.250) M | 0.051 M | 2.223 (1.187–4.163) M | 0.013 M | M | |
| Garcia-Donas, 2011 | GG vs AA | 3.57 (1.75–7.30) M | 0.0079 M | 1.77 (0.65–4.84) M | 0.26 M | M | |
| VEGFR3 rs448012 (C>G) | Liu, 2017 | CC vs GG | NA | NA | 4.113 (3.593–5.942) U | < 0.001 U | U |
| Garcia-Donas, 2011 | GG vs CC | 1.12 (0.68–1.85) M | 0.66 M | 1.36 (0.71–2.59) M | 0.35 M | M | |
| VEGFR3 rs307821 (G>T) | Dornbusch, 2016 | TT+TG vs GG | 1.351 (0.388–4.707) M 0.722 (0.438–1.190) U | 0.636 M 0.201 U | 1.349 (0.226–8.066) M 1.239 (0.637–2.408) U | 0.743 M 0.528 U | M/U |
| Beuselinck, 2013 | TT+TG vs GG | 1.981(1.060–3.702) M | 0.032 M | 2.265(1.202–4.268) M | 0.011 M | M | |
| Garcia-Donas, 2011 | TT vs GG | 3.31 (1.64–6.68) M | 0.014 M | 1.24 (0.41–3.75) M | 0.71 M | M |
The source of HR and 95% CI was extracted from survival curves or article reports.
HRs, hazard ratios; 95% CI, 95% confidence interval; M, multivariate analysis; U, univariate analysis.
SNPs, single-nucleotide polymorphisms; VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor; OS, overall survival; PFS, progression-free survival.